<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01221922</url>
  </required_header>
  <id_info>
    <org_study_id>C67-10-A</org_study_id>
    <nct_id>NCT01221922</nct_id>
  </id_info>
  <brief_title>Laser Treatment of Acne Scars in Fitzpatrick Skin Types III-VI</brief_title>
  <official_title>A Study of the RevLite Q-Switched Neodymium: Yttrium-Aluminum-Garnet (Nd:YAG) Laser for the Treatment of Acne Scars in Fitzpatrick Skin Types III-VI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ConBio, a Cynosure Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the RevLite Q-Switched Neodymium:
      Yttrium-Aluminum-Garnet (Nd:YAG) Laser in the treatment of acne scars in darker skin types
      (Fitzpatrick Skin Types III, IV, V and VI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Acne Scarring Classification</measure>
    <time_frame>3 Months post final treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction</measure>
    <time_frame>3 Months post final treatment</time_frame>
    <description>5 point Likert scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acne Scars</condition>
  <arm_group>
    <arm_group_label>Acne treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of acne scars</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RevLite Q-Switched Nd:YAG Laser</intervention_name>
    <description>Laser treatment once every 2 weeks for a total of 10 treatments.</description>
    <arm_group_label>Acne treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older with Fitzpatrick Skin Type III, IV, V or VI

          -  Evidence of atrophic scarring

        Exclusion Criteria:

          -  Pregnancy, lactating or planning to become pregnant during the study

          -  History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins
             or photodermatosis

          -  Any skin pathology or condition that could interfere with the evaluation or requires
             the use of interfering topical or systemic therapy

          -  Any condition which, in the investigator's opinion, would make it unsafe for the
             subject to participate

          -  Currently enrolled in an investigational drug or device trial, or has received an
             investigational drug or been treated with an investigational device within 30 days
             prior to entering the study

          -  Subject is unable to communicate or cooperate with the investigator due to language
             problems, poor mental development, or impaired cerebral function

          -  Subject may be unreliable for the study. This includes subjects who engage in
             excessive alcohol intake or drug abuse, or subjects who are unable to return for
             scheduled follow-up visits

          -  Use of oral or topical isotretinoin therapy within 6 months prior to enrollment. With
             the exception of isotretinoin, subjects will be allowed to continue their topical or
             oral acne medications during the trial

          -  Need to be exposed to artificial tanning devices or excessive sunlight during the
             trial

          -  Prior treatment with parenteral gold therapy

          -  Diabetes Type I or II, Lupus, Scleroderma or a similar immune system disorder

          -  Subject does not agree to refrain from any other type of facial skin resurfacing
             (e.g., microdermabrasion, laser or IPL treatment, chemical peel) or injected
             filler/other substances (e.g., Restylane, Botox) that might affect the treatment area
             for the duration of the study

          -  Underlying silicone or other nonabsorbable fillers in the treatment area or has had
             filler (e.g., collagen, fat) injections within the past 3 months

          -  History of keloidal scarring or nodulocystic acne

          -  Phenol or chemical peel or dermabrasion to the the treatment area within the past 6
             months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niwat Polnikorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasemrad Aesthetic Center, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasemrad Aesthetic Center, Kasemrad Prachacheun Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

